Gary S. Hogge

SVP,Clinical & Medical Affairs, Lineage Cell Therapeutics.

Companies

Lineage Cell TherapeuticsSVP,Clinical & Medical Affairs Mar 29, 2019 to Mar 10, 2023¹

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

As of each latest filing. The line shows shares held over time.

Feb 11, 2023Shares withheld for tax 5,310 shares at $1.35 of Lineage Cell Therapeutics²
Feb 11, 2023Exercised options 13,020 shares of Lineage Cell Therapeutics²
Dec 29, 2021Sold 28,445 shares at $2.44 of Lineage Cell Therapeutics³
Dec 29, 2021Sold 9,250 shares at $2.49 of Lineage Cell Therapeutics³
Dec 29, 2021Exercised options 9,250 shares at $0.69 of Lineage Cell Therapeutics³
Dec 28, 2021Sold 501,588 shares at $2.45 of Lineage Cell Therapeutics³
Dec 28, 2021Exercised options 79,689 shares at $1.14 of Lineage Cell Therapeutics³
Dec 28, 2021Exercised options 236,899 shares at $2.11 of Lineage Cell Therapeutics³
Dec 28, 2021Exercised options 185,000 shares at $0.69 of Lineage Cell Therapeutics³

The numbers on this page point here. Each one links to the record it came from.